Utility of procalcitonin, neopterin, C-reactive protein and MR-proANP measurement in the management of exacerbations in chronic obstructive pulmonary disease Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008
C-reactive protein levels and clinically important predictive outcomes in stable COPD patients Source: Eur Respir J 2006; 27: 902-907 Year: 2006
Evaluation of procalcitonin (PCT) and neopterin levels in acute exacerbations of COPD Source: Annual Congress 2005 - Acute and chronic infections in COPD Year: 2005
Individual variation in the levels of procalcitonin, neopterin, CRP and MR-proANP during a COPD exacerbation and clinical stable state Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment Year: 2009
The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease Source: Eur Respir J 2007; 30: Suppl. 51, 363s Year: 2007
Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Source: Eur Respir J 2008; 32: 1451-1457 Year: 2008
Factors affecting C-reactive protein levels in patients with chronic obstructive pulmonary disease Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007
Combined serum eosinophil count and procalcitonin level as a marker of bacterial infection in acute exacerbation of chronic obstructive pulmonary disease Source: International Congress 2016 – Systemic biomarkers Year: 2016
Body composition and plasma levels of inflammatory biomarkers in COPD Source: Eur Respir J 2010; 36: 1027-1033 Year: 2010
Genetically elevated C-reactive protein and chronic obstructive pulmonary disease Source: Annual Congress 2009 - Environmental and genetic risk factors for asthma and COPD Year: 2009
Selected blood parameters of inflammation (circulating immune complexes, CIC, C-reactive protein, CRP, neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio) in patients with chronic obstructive pulmonary disease (COPD) Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD Year: 2020
C-reactive protein and serum amyloid A overexpression in lung tissues of chronic obstructive pulmonary disease patients Source: Annual Congress 2012 - Inflammatory mechanisms in COPD Year: 2012
Differences in cellular expression of C-reactive protein and serum amyloid A in lung tissue in patients with chronic obstructive pulmonary disease Source: Annual Congress 2012 - Inflammatory mechanisms in COPD Year: 2012
Evaluation of neutrophil lymphocyte ratio and C-reactive protein values in the treatment of acute chronic obstructive pulmonary disease exacerbation according to endotype Source: Virtual Congress 2020 – Monitoring of patients with COPD Year: 2020
Performance of rapid, bedside whole blood C-reactive protein (CRP) test as a diagnostic test for bacterial infection and pneumonia in patients with acute exacerbation of chronic obstructive pulmonary disease (AE COPD) Source: Eur Respir J 2007; 30: Suppl. 51, 557s Year: 2007
D-dimer to C-reactive protein (CRP) ratio in patients with suspected pulmonary embolism Source: Annual Congress 2010 - Pulmonary embolism Year: 2010
Levels of procalcitonin, neopterin, C-reactive protein and pro-atrial natriuretic peptide in patients with community-acquired pneumonia and its kinetic according to the severity and the development of complications Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
C-reactive protein (CRP) as a risk marker in COPD patients with ischaemic heart disease Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008
C-reactive protein usefulness in diagnosis and follow-up of COPD infectious exacerbations Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007
Serum interferon-gamma levels in chronic obstructive pulmonary disease and asthma patients: correlation with respiratory parameters Source: Eur Respir J 2001; 18: Suppl. 33, 75s Year: 2001